Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Lung inflammatory injury and tissue repair (Jul 2023)
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI117102

Adenosine triphosphate-dependent transport of doxorubicin, daunomycin, and vinblastine in human tissues by a mechanism distinct from the P-glycoprotein.

S Awasthi, S S Singhal, S K Srivastava, P Zimniak, K K Bajpai, M Saxena, R Sharma, S A Ziller 3rd, E P Frenkel, and S V Singh

Department of Internal Medicine, University of Texas Medical Branch, Galveston 77555.

Find articles by Awasthi, S. in: JCI | PubMed | Google Scholar

Department of Internal Medicine, University of Texas Medical Branch, Galveston 77555.

Find articles by Singhal, S. in: JCI | PubMed | Google Scholar

Department of Internal Medicine, University of Texas Medical Branch, Galveston 77555.

Find articles by Srivastava, S. in: JCI | PubMed | Google Scholar

Department of Internal Medicine, University of Texas Medical Branch, Galveston 77555.

Find articles by Zimniak, P. in: JCI | PubMed | Google Scholar

Department of Internal Medicine, University of Texas Medical Branch, Galveston 77555.

Find articles by Bajpai, K. in: JCI | PubMed | Google Scholar

Department of Internal Medicine, University of Texas Medical Branch, Galveston 77555.

Find articles by Saxena, M. in: JCI | PubMed | Google Scholar

Department of Internal Medicine, University of Texas Medical Branch, Galveston 77555.

Find articles by Sharma, R. in: JCI | PubMed | Google Scholar

Department of Internal Medicine, University of Texas Medical Branch, Galveston 77555.

Find articles by Ziller, S. in: JCI | PubMed | Google Scholar

Department of Internal Medicine, University of Texas Medical Branch, Galveston 77555.

Find articles by Frenkel, E. in: JCI | PubMed | Google Scholar

Department of Internal Medicine, University of Texas Medical Branch, Galveston 77555.

Find articles by Singh, S. in: JCI | PubMed | Google Scholar

Published March 1, 1994 - More info

Published in Volume 93, Issue 3 on March 1, 1994
J Clin Invest. 1994;93(3):958–965. https://doi.org/10.1172/JCI117102.
© 1994 The American Society for Clinical Investigation
Published March 1, 1994 - Version history
View PDF
Abstract

Previous studies have demonstrated that a human glutathione conjugate transporter, designated as dinitrophenyl-S-glutathione ATPase (DNP-SG ATPase), catalyzed ATP hydrolysis in the presence of several amphiphilic compounds other than glutathione conjugates (Singhal, S. S., R. Sharma, S. Gupta, H. Ahmad, P. Zimniak, A. Radominska, R. Lester, and Y. C. Awasthi. 1991. FEBS [Fed. Eur. Biochem. Soc.] Lett. 281:255-257). We now demonstrate that DNP-SG ATPase purified from human lung and erythrocyte membranes catalyzed the hydrolysis of ATP in the presence of doxorubicin and its metabolites. Doxorubicin-stimulated ATP hydrolysis by DNP-SG ATPase was saturable with respect to doxorubicin (Km 1.2 and 2.8 microM for the lung and erythrocyte enzymes, respectively). Antibodies against DNP-SG ATPase immunoprecipitated the ATP hydrolyzing activity stimulated by doxorubicin, its metabolites, and glutathione conjugates. Inside our vesicles prepared from erythrocyte membranes took up doxorubicin, daunomycin, and vinblastine in an ATP-dependent manner. The uptake was linear with respect to time and vesicle protein, was dependent on ATP and magnesium, was inhibited by heavy metal salts or by heating the vesicles, and was sensitive to both osmolarity and orientation of the vesicles. The transport had an activation energy of 13 kcal/mol, was saturable with respect to both doxorubicin and ATP (Km values of 1.8 microM and 1.9 mM, respectively), and was competitively inhibited by glutathione conjugates as well as by a number of amphiphiles such as daunomycin or vinblastine. Transport was diminished upon coating the vesicles with antibodies against DNP-SG ATPase. Incorporation of increasing amounts of purified DNP-SG ATPase into the vesicles resulted in a linear increase in transport of doxorubicin. These studies demonstrated for the first time that a membrane protein that catalyzed the transport of anionic amphiphilic molecules such as glutathione conjugates could also mediate the transport of weakly cationic antitumor antibiotic, doxorubicin. Notably, the Km of transport was in the range of doxorubicin concentration achievable in human serum after intravenous dosing of doxorubicin.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 958
page 958
icon of scanned page 959
page 959
icon of scanned page 960
page 960
icon of scanned page 961
page 961
icon of scanned page 962
page 962
icon of scanned page 963
page 963
icon of scanned page 964
page 964
icon of scanned page 965
page 965
Version history
  • Version 1 (March 1, 1994): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts